New Complete Response in the Concurrent BTKi azer-cel Cohort

• Additional complete response in BTKi cohort
• First Mantle Cell Lymphoma patient treated
• Patient had previously failed BTKi therapy

Imugene Limited (ASX: IMU) announced an additional complete response in the concurrent BTKi cohort of its ongoing Phase 1b study of azer-cel (azercabtagene zapreleucel). This Mantle Cell Lymphoma (MCL) patient, the first MCL patient treated in the azer-cel Phase 1b study, had previously failed BTKi therapy and achieved a complete response at the Day 28 assessment. MCL is an aggressive B-cell non-Hodgkin lymphoma that typically presents at an advanced stage and remains incurable with standard therapies. BTK inhibitors have become an established treatment across relapsed or refractory MCL, but a significant proportion of patients develop resistance over time, leaving them with limited remaining options.